Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of October 15, 2026, KRYS trades at $326.70 with a market cap of $9.51B and a P/E ratio of 39.93. KRYS moved -1.21% today. Year to date, KRYS is +33.93%; over the trailing twelve months it is +75.85%. Its 52-week range spans $122.80 to $382.54. Analyst consensus is strong buy with an average price target of $409.29. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
9 analysts cover KRYS: 0 strong buy, 8 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $409.29.
| Metric | Value |
|---|---|
| Price | $326.70 |
| Market Cap | $9.51B |
| P/E Ratio | 39.93 |
| EPS | $8.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $382.54 |
| 52-Week Low | $122.80 |
| Volume | 91 |
| Avg Volume | 0 |
| Revenue (TTM) | $440.48M |
| Net Income | $241.47M |
| Gross Margin | 0.00% |
9 analysts cover KRYS: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $409.29.